Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer immunology research

• Publication date

  2017-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-16-0061-TPMID 28073775
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

  2016cited by this paper
• Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

  2016cited by this paper
• Location, location, location

  2014cited by this paper
• Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints

  2014cited by this paper
• Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

  2014cited by this paper
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

  2014cited by this paper
• Location, location, location.

  2014cited by this paper
• Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment

  2014cited by this paper
• Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

  2014cited by this paper
• Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

  2014cited by this paper
• Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

  2013influential reference
• Immunomodulatory Effects of Tyrosine Kinase Inhibitors

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Strong emerging rationale for combining oncogene-targeted agents with immunotherapy

  2013cited by this paper
• Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study

  2013cited by this paper
• Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

  2012cited by this paper
• Dasatinib combined with docetaxel for castration‐resistant prostate cancer

  2012cited by this paper
• Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

  2012cited by this paper
• Dasatinib inhibits proinflammatory functions of mature human neutrophils

  2012cited by this paper
• Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

  2011cited by this paper
• Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011influential reference
• Dasatinib in solid tumors

  2010cited by this paper
• The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

  2010cited by this paper
• Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo

  2010cited by this paper
• Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

  2010cited by this paper
• Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

  2010cited by this paper
• Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

  2008cited by this paper
• The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.

  2008cited by this paper
• PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes1

  2008cited by this paper
• Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

  2008cited by this paper
• Specific growth rate versus doubling time for quantitative characterization of tumor growth rate.

  2007cited by this paper
• Adaptive immunity maintains occult cancer in an equilibrium state

  2007cited by this paper
• Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

  2007cited by this paper
• Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

  2007cited by this paper
• Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

  2006cited by this paper
• Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• NK and CD8+ T cell‐mediated eradication of poorly immunogenic B16‐F10 melanoma by the combined action of IL‐12 gene therapy and 4‐1BB costimulation

  2004cited by this paper
• Src family kinases, key regulators of signal transduction

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

  2003cited by this paper
• Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses.

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• Costimulation of T cells for tumor immunity.

  1993cited by this paper
• A Prognostic Model for Clinical Stage I Melanoma of the Upper Extremity. The Importance of Anatomic Subsites in Predicting Recurrent Disease

  1981cited by this paper

• Inhibiting the Secreted RGDKGE Collagen Peptide Selectively Controls CD8+ T-Cell Migration on Denatured Collagen-IV and Enhances Their Accumulation in Tumors

  2026cites this paper
• Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity

  2026cites this paper
• Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung).

  2026cites this paper
• Application of mass cytometry in the immune microenvironment of breast cancer

  2025cites this paper
• Antitumor efficacy of intermittent low‐dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche

  2025cites this paper
• Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma

  2025cites this paper
• Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway

  2025cites this paper
• Dasatinib Inhibits Basal B Breast Cancer Through ETS1-Mediated Extracellular Matrix Remodeling

  2025cites this paper
• Reprogram to heal: Macrophage phenotypes as living therapeutics.

  2025cites this paper
• A Platelet-Powered Drug Delivery System for Enhancing Chemotherapy Efficacy for Liver Cancer Using the Trojan Horse Strategy

  2024cites this paper
• SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition

  2024cites this paper
• Improvement of tumor neoantigen detection by high field asymmetric waveform ion mobility mass spectrometry.

  2024cites this paper
• Functional roles of SRC signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities

  2023cites this paper
• Fluorescent Detection of Peroxynitrite Produced by Myeloid-Derived Suppressor Cells in Cancer and Inhibition by Dasatinib.

  2023cites this paper
• Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation

  2023cites this paper
• Dasatinib-induced spleen contraction leads to transient lymphocytosis

  2022cites this paper
• NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders?

  2022cites this paper
• Regulation of hematopoietic and leukemia stem cells by regulatory T cells

  2022cites this paper
• Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition

  2022cites this paper
• pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer.

  2022cites this paper
• Recent progress in SRC targeted therapy for pancreatic cancer

  2021cites this paper
• Immunity against Chronic Myeloid Leukemia KIR3DL1 Allotype-Dependent Modulation of NK Cell

  2021influential citation
• KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia

  2021cites this paper
• Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades

  2021cites this paper
• SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

  2021influential citation
• Transient “rest” restores functionality in exhausted CAR-T cells via epigenetic remodeling

  2021cites this paper
• CyTOF: An Emerging Technology for Single‐Cell Proteomics in the Mouse

  2021cites this paper
• SFKs in intestine

  2020cites this paper
• Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib

  2020cites this paper
• Transient “rest” induces functional reinvigoration and epigenetic remodeling in exhausted CAR-T cells

  2020cites this paper
• Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia

  2020cites this paper
• Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis

  2020cites this paper
• HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

  2020cites this paper
• Targeted Delivery of Dasatinib to Deplete Tumor-Associated Macrophages by Mannosylated Mixed Micelles for Tumor Immunotherapy.

  2020cites this paper
• Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles.

  2020cites this paper
• Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis

  2019cites this paper
• University of Southern Denmark High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

  2019cites this paper
• Syddansk Universitet High-Parameter Mass Cytometry Evaluation of Relapsed / Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

  2019cites this paper
• Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy

  2019cites this paper
• Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

  2019cites this paper
• NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

  2019cites this paper
• Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

  2019cites this paper
• Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors

  2018cites this paper
• The tyrosine kinase inhibitor dasatinib reduces the growth of intracellular Mycobacterium tuberculosis despite impairing T‐cell function

  2018cites this paper
• Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

  2018cites this paper
• Cutaneous Melanoma—A Long Road from Experimental Models to Clinical Outcome: A Review

  2018cites this paper
• Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML

  2018cites this paper
• High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action

  2018cites this paper
• EVALUATION OF T- REGULATORY CELLS IN BREAST CANCER.

  2017cites this paper
• Kinase inhibitors in clinical practice: An expanding world.

  2017cites this paper
• Simultaneous Detection of Protein and mRNA in Jurkat and KG‐1a Cells by Mass Cytometry

  2017cites this paper
• Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner

  2017cites this paper